Here are three things to know.
- The Parkinson’s drug levodopa can cause dyskinesia, or uncontrolled, involuntary movement.
- Gocovri is a once-daily drug intended to control levodopa-induced dyskinesia. The drugs main ingredient, amantadine, has been on the market for several decades as an antiviral drug.
- Adamas Pharmaceuticals expects the drug to be available in the fourth quarter of this year and formally launch in January 2018.
More articles on supply chain:
US Bioservices to pay $13.4M to resolve kickback suit
Samsung widens stake in prescription drug market through partnership with Japanese pharmaceutical company
Patients brace for price of ‘breakthrough’ leukemia drug CTL019
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
